Esplanade Ventures

Co-Founders Dr. Sheldon Elman and Stuart Elman oversee the firm's strategy and investment decisions alongside Managing Partner Ella Seitz and Venture Partner Josh Blair. The firm operates with a lean team of nine, including Principal Alexandre Nossovskoi. No external investment committee structure is publicly disclosed.

Esplanade sources opportunities through a network built on decades of healthcare operations. The founding team's clinical and management experience provides direct access to hospital systems, healthtech founders, and clinical validators across North America and Israel. The firm does not publicly disclose a systematic outbound sourcing program, but its operator-led thesis prioritizes deals surfaced through practitioner networks rather than traditional venture pipelines.

Esplanade invests from Seed through Series A, with selective follow-on participation in Series B rounds. The firm leads or co-leads early-stage rounds in digital health companies focused on North American commercialization. It does not reveal standard check sizes or reserve ratios.

Esplanade operates as a direct venture investor, not a fund-of-funds. The firm makes direct equity investments into operating companies. There is no public record indicating fund commitments to external GPs or participation in LP positions.

The firm states explicitly on its website that it does not invest in invasive medical devices or biotechnology. Esplanade concentrates solely on digital health, with a preference for AI-enabled software platforms. It maintains no exposure to hardware, life sciences, or therapeutic development.

Chairman Dr. Sheldon Elman brings over 45 years in healthcare, while Co-Founder Stuart Elman adds 20 years. Venture Partner Josh Blair contributes 15 years in healthtech from his tenure at TELUS, one of Canada's largest healthcare IT providers. The firm markets itself as 'healthcare operators backing healthcare innovators' rather than career investors entering the space.

Esplanade targets companies commercializing in North America, with a team and network that extend to Europe and Israel. The dual-office structure in Montreal and Toronto supports Canadian deal flow, but the firm actively seeks U.S.-focused opportunities. It does not disclose formal allocations by country or region.